Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib, , Cyclophosphamide, Dexamethasone

Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.

Trial Locations (2)

119074

National University Hospital, Singapore

169608

Singapore General Hospital, Singapore

All Listed Sponsors
lead

Singapore General Hospital

OTHER

NCT02217163 - Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma | Biotech Hunter | Biotech Hunter